Compare PRG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRG | MIRM |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 3.4B |
| IPO Year | N/A | 2019 |
| Metric | PRG | MIRM |
|---|---|---|
| Price | $29.98 | $78.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $37.50 | ★ $92.45 |
| AVG Volume (30 Days) | 665.7K | ★ 790.7K |
| Earning Date | 10-22-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | ★ 10.59 | N/A |
| EPS | ★ 3.96 | N/A |
| Revenue | ★ $2,507,179,000.00 | $471,794,000.00 |
| Revenue This Year | $1.32 | $53.78 |
| Revenue Next Year | $0.64 | $19.91 |
| P/E Ratio | $7.56 | ★ N/A |
| Revenue Growth | 3.71 | ★ 53.66 |
| 52 Week Low | $23.50 | $36.88 |
| 52 Week High | $44.43 | $79.95 |
| Indicator | PRG | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 69.86 |
| Support Level | $29.38 | $63.23 |
| Resistance Level | $31.26 | $66.77 |
| Average True Range (ATR) | 1.01 | 3.33 |
| MACD | 0.10 | 0.90 |
| Stochastic Oscillator | 60.30 | 98.15 |
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.